Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor notch2 in splenic marginal zone lymphoma

Journal of Molecular Diagnostics

Volumn 6, Issue 4, 2004, Pages 297-307

  Trøen, Gunhild ^a   Nygaard, Vigdis ^a   Jenssen, Tor Kristian ^b   Ikonomou, Ida Münster ^a   Tierens, Anne ^a   Matutes, Estella ^c   Gruszka Westwood, Alicja ^c   Catovsky, Daniel ^c   Myklebost, Ola ^a   Lauritzsen, Grete ^a   Hovig, Eivind ^a   Delabie, Jan ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Pubgene Inc   (Norway)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HELICASE; IMMUNOGLOBULIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P53; RNA; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; AUTOREGULATION; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GRADING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 7Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DNA MICROARRAY; EXCISION REPAIR; FROZEN SECTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DIFFERENTIATION; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SPLEEN CANCER; TISSUE SECTION; UPREGULATION;

EID: 8744307100     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-1578(10)60525-9     Document Type: Article

References (38)

1. Thieblemont C, Felman P, Callet-Bauchu E, Traverse-Glehen A, Salles G, Berger F, Coiffier B: Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003, 4:95-103
2. Maes B, Wolf-Peeters C: Marginal zone cell lymphoma: an update on recent advances. Histopathology 2002, 40:117-126
3. Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martinez P, Piris MA: 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999, 154:1583-1589
4. Gruszka-Westwood AM, Hamoudi R, Osborne L, Matutes E, Catovsky D: Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes. Genes Chromosomes Cancer 2003, 36:57-69
5. Dierlamm J, Pittaluga S, Wlodarska I, Stul M, Thomas J, Boogaerts M, Michaux L, Driessen A, Mecucci C, Cassiman JJ: Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996, 87:299-307
6. Oscier DG, Matutes E, Gardiner A, Glide S, Mould S, Brito-Babapulle V, Ellis J, Catovsky D: Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol 1993, 85:487-491
7. Tierens A, Delabie J, Malecka A, Wang J, Gruszka-Westwood A, Catovsky D, Matutes E: Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. Am J Pathol 2003, 162:681-689
8. Algara P, Mateo MS, Sanchez-Beato M, Mollejo M, Navas IC, Romero L, Sole F, Salido M, Florensa L, Martinez P, Campo E, Piris MA: Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002, 99:1299-1304
9. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347:89-94
10. Bates I, Bedu-Addo G, Rutherford T, Bevan DH: Splenic lymphoma with villous lymphocytes in tropical West Africa. Lancet 1992, 340: 575-577
11. Sonoki T, Harder L, Horsman DE, Karran L, Taniguchi I, Willis TG, Gesk S, Steinemann D, Zucca E, Schlegelberger B, Sole F, Mungall AJ, Gascoyne RD, Siebert R, Dyer MJ: Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood 2001, 98: 2837-2844
12. Brito-Babapulle V, Gruszka-Westwood AM, Platt G, Andersen CL, Elnenaei MO, Matutes E, Wotherspoon AC, Weston-Smith SG, Catovsky D: Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica 2002, 87:357-362
13. Staudt LM: Molecular diagnosis of the hematologic cancers. N Engl J Med 2003, 348:1777-1785
14. Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D: p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 2001, 97:3552-3558
15. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours: Pathoiogy and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001
16. Nygaard V, Loland A, Holden M, Langaas M, Rue H, Liu F, Myklebost O, Fodstad O, Hovig E, Smith-Sorensen B: Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance. BMC Genomics 2003, 4:11
17. Baugh LR, Hill AA, Brown EL, Hunter CP: Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res 2001, 29:E29
18. Basirico R, Pirrotta R, Fabbiano F, Mirto S, Cascio L, Pagano M, Cammarata G, Magrin S, Santoro A: Submicroscopic deletions at 7q region are associated with recurrent chromosome abnormalities in acute leukemia. Haematologica 2003, 88:429-437
19. Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400
20. van Dam H, Castellazzi M: Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 2001, 20:2453-2464
21. Vogt PK: Jun, the oncoprotein. Oncogene 2001, 20:2365-2377
22. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ: Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003, 101:1513-1519
23. Mathes S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dorken B, Scheidereit C: Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation, and synergize with NF-kappa B. EMBO J 2002, 21:4104-4113
24. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M: Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 2000, 19:2056-2068
25. Pear WS, Radtke F: Notch signaling in lymphopoiesis. Semin Immunol 2003, 15:69-79
26. Baron M: An overview of the Notch signalling pathway. Semin Cell Dev Biol 2003, 14:113-119
27. Kuroda K, Han H, Tani S, Tanigaki K, Tun T, Furukawa T, Taniguchi Y, Kurooka H, Hamada Y, Toyokuni S, Honjo T: Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity 2003, 18:301-312
28. Tanigaki K, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kurodo K, Suzuki A, Nakano T, Honjo T: Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol 2002, 3:443-450
29. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke M, Berger R: Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 2002, 99:3742-3747
30. Chu J, Jeffries S, Norton JE, Capobianco AJ, Bresnick EH: Repression of activator protein-1-mediated transcriptional activation by the Notch-1 intracellular domain. J Biol Chem 2002, 277:7587-7597
31. Vasanwala FH, Kusam S, Toney LM, Dent AL: Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 2002, 169:1922-1929
32. Samstag Y, Eibert SM, Klemke M, Wabnitz GH: Actin cytoskeletal dynamics in T lymphocyte activation and migration. J Leukoc Biol 2003, 73:30-48
33. Catovsky D, Matutes E: Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999, 36:148-154
34. Roberts T, Chernova O, Cowell JK: NB4S, a member of the TBC1 domain family of genes, is truncated as a result of a constitutional t(1;10)(p22;q21) chromosome translocation in a patient with stage 4S neuroblastoma. Hum Mol Genet 1998, 7:1169-1178
35. Knorr C, Amrehn C, Seeberger H, Rosenwald A, Stilgenbauer S, Ott G, Muller Hermelink HK, Greiner A: Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo. Am J Pathol 1999, 155:2019-2027
36. Piek E, Roberts AB: Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. Adv Cancer Res 2001, 83:1-54
37. Bernstein C, Bernstein H, Payne CM, Garewal H: DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002, 511:145-178
38. Wang Q, Zhu Q, Wani MA, Wani G, Chen J, Wani AA: Tumor suppressor p53-dependent recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage. DNA Repair (Amst) 2003, 2:483-499